Feed CRL
CR

Charles River Laboratories

CRL · NYSE

$288.99 +3.58% (+$9.98)
1M -6.55%
Market Cap $13.4B
P/E Ratio -
Div. Yield -
ROE 7.72%

Bulios Fair Price

$215.7

25.4% downside

Current Price

$288.99

Undervalued Fair Value Overvalued

According to Bulios Fair Price, CRL is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
25 /100
Expensive
P/S 3.36x
P/B 4.73x
P/FCF 36.26x
Growth
50 /100
Stable
FCF growth 20.69%
Book val. growth 2.07%
Rev. growth 0.33%
Profitability
46 /100
Moderate
Net margin 5.96%
Op. margin 12.35%
FCF margin 9.27%
Quality
29 /100
Poor
ROE 7.72%
ROA 3.17%
Asset turnover 0.53x
Debt
24 /100
High
Current ratio 1.35x
Int. coverage -0.73x
Net debt/EBITDA 12.86x
Stability
41 /100
Moderate
Rev. volatility 3.08%
EPS volatility 870.05%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CRL
Online

About the company

Charles River Laboratories International, Inc. (CRL) is an American company operating in the biotechnology and pharmaceutical research industry. The company specializes in providing preclinical and clinical services to pharmaceutical and biotechnology companies, academic institutions, and government organizations. Its services include drug testing, toxicity studies, pharmacokinetics, viral safety testing, genetic analysis, and other biological and chemical analyses. Charles River Laboratories has a broad portfolio of laboratory and clinical services that are crucial for the development of new drugs and treatment protocols. The company emphasizes quality, innovation, and ethical standards in its research and laboratory practices. It is recognized as a significant partner for the pharmaceutical and biotechnology sectors. Charles River Laboratories International, Inc. (CRL) shares are publicly traded on the stock exchange and may represent an attractive investment opportunity for investors monitoring the biotechnology and pharmaceutical industry and seeking investments in a company with a significant position in drug research and development.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Birgit Girshick

Employees

19,000

Headquarters

Wilmington

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.